Annoviant

Annoviant, LLC, formerly known as TGen Tech LLC, is a medical device company established in 2018. It currently collaborates with a broad ecosystem, including research institutions and industry partners across China. Driven by the personal experiences of its co-founders, the company is motivated to positively impact the lives and treatment of patients with congenital heart disease (CHD). The new TxGuard™ device portfolio addresses clinical challenges and significantly reduces healthcare costs by eliminating the need for repeat surgeries. The company is developing cardiovascular devices for structural heart therapies.